IMIan G. Mills

Ian G. Mills

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ian G. Mills has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • 942 The androgen receptor induces a distinct transcriptional program in castration resistant prostate cancer in man

    by N.L. Sharma, C.E. Massie, A. Ramos-Montoya, H.E. Scott, R. Stark, A.Y. Warren, I.G. Mills, D.E. Neal


  • A role for neurotensin in bicalutamide resistant prostate cancer cells

    by Maria Vias, Glyn Burtt, Zoran Culig, Abhi Veerakumarasivam, David E. Neal, Ian G. Mills

    BACKGROUND Anti-androgens are administered as a principal treatment for prostate cancer. Aggressive hormone refractory disease is characterized in some cases by the development of a neuroendocrine phenotype. However little attention has been paid to resistance pathways selected for by long-term treatment with non-steroidal anti-androgens. METHODS Using a resistant sub-line, LNCaP-Bic, we performed a comparative gene expression profiling using cDNA microarrays and target validation by qRT-PCR. Targets were then explored using cell proliferation, cell cycle analysis and in vitro invasion assays using siRNA technology. RESULTS Neurotensin/Neuromedin N (NTS) was upregulated in the LNCaP-Bic line at both the transcript and protein level. The resistant line was found to have an increased proliferation rate, more rapid cell cycle progression and increased invasiveness through Matrigel. Each phenotypic difference could be reduced using siRNA knockdown of NT. CONCLUSION Increased expression of NT in bicalutamide resistant prostate cancer cells induces cell proliferation and invasion suggesting that this peptide may contribute to the development of bicalutamide resistant prostate cancer. Prostate


  • The developing role of receptors and adaptors

    by Charles Massie, Ian G. Mills

    Recent data indicate that growth-factor receptors and associated adaptors can accumulate in the nucleus. Are there novel functions for these proteins that might change our understanding of their role in cancer, and do these findings have implications for drug resistance? The response of a cell to the myriad of signals that it receives is varied, and it is dependent on many different factors. The most-studied responses involve growth-factor signalling and these signalling cascades have become key targets for cancer therapy. Recent reports have indicated that growth-factor receptors and associated adaptors can accumulate in the nucleus. Are there novel functions for these proteins that might affect our understanding of their role in cancer and have implications for drug resistance?


  • Open Access

    Huntingtin interacting protein 1 modulates the transcriptional activity of nuclear hormone receptors

    by Ian G. Mills, Luke Gaughan, Craig Robson, Theodora Ross, Stuart McCracken, John Kelly, David E. Neal

    Internalization of activated receptors regulates signaling, and endocytic adaptor proteins are well-characterized in clathrin-mediated uptake. One of these adaptor proteins, huntingtin interacting protein 1 (HIP1), induces cellular transformation and is overexpressed in some prostate cancers. We have discovered that HIP1 associates with the androgen receptor through a central coiled coil domain and is recruited to DNA response elements upon androgen stimulation. HIP1 is a novel androgen receptor regulator, significantly repressing transcription when knocked down using a silencing RNA approach and activating transcription when overexpressed. We have also identified a functional nuclear localization signal at the COOH terminus of HIP1, which contributes to the nuclear translocation of the protein. In conclusion, we have discovered that HIP1 is a nucleocytoplasmic protein capable of associating with membranes and DNA response elements and regulating transcription.